Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Costantine Albany
- Registration Number
- NCT03960151
Olanzapine Versus Midazolam for Agitation
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Hennepin Healthcare Research Institute
- Target Recruit Count
- 206
- Registration Number
- NCT03899506
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 96
- Registration Number
- NCT03877562
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Clozapine Versus Olanzapine as Treatment for Comorbid Psychotic Disorder and Substance Use Disorder
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Augusta University
- Target Recruit Count
- 100
- Registration Number
- NCT03857581
- Locations
- 🇺🇸
Sandarsh Surya, Evans, Georgia, United States
Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals
- Conditions
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 2700
- Registration Number
- NCT03790085
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 24
- Registration Number
- NCT03781115
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Banner University Medical Center, Phoenix, Arizona, United States
Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
- Conditions
- Interventions
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Calo Psychiatric Center
- Target Recruit Count
- 111
- Registration Number
- NCT03730857
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2018-09-20
- Lead Sponsor
- Khon Kaen University
- Target Recruit Count
- 15
- Registration Number
- NCT03679182
- Locations
- 🇹🇭
Jarin Chindaprasirt, Khon Kaen, Thailand
Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Instituto do Cancer do Estado de São Paulo
- Target Recruit Count
- 100
- Registration Number
- NCT03631004
- Locations
- 🇧🇷
Cancer Institute of the State of Sao Paulo - ICESP, Sao Paulo, São Paulo, Brazil
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 690
- Registration Number
- NCT03578081
- Locations
- 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸Hurley Medical Center, Flint, Michigan, United States
🇺🇸Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.